Last reviewed · How we verify
NCT07258446
PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma
NA trial testing Immunohistochemistry Staining Method in Clinical Stage 0 Cutaneous Melanoma AJCC v8 in 36 participants. Currently enrolling.
1 December 2028
Quick facts
| Lead sponsor | University of California, Davis |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 24 October 2025 |
| Primary completion | 1 December 2028 |
| Estimated completion | 1 November 2033 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Immunohistochemistry Staining Method
- Mohs Surgery
Conditions studied
- Clinical Stage 0 Cutaneous Melanoma AJCC v8 — all drugs for Clinical Stage 0 Cutaneous Melanoma AJCC v8 →
- Clinical Stage I Cutaneous Melanoma AJCC v8 — all drugs for Clinical Stage I Cutaneous Melanoma AJCC v8 →
- Clinical Stage II Cutaneous Melanoma AJCC v8 — all drugs for Clinical Stage II Cutaneous Melanoma AJCC v8 →
Sponsor
University of California, Davis
Who can join
18 and older, any sex, with Clinical Stage 0 Cutaneous Melanoma AJCC v8 or Clinical Stage I Cutaneous Melanoma AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial tests the addition of preferentially expressed antigen in melanoma (PRAME) immunohistochemical (IHC) staining to standard slow Mohs micrographic surgery (SMMS) for guiding tissue removal in patients with stage 0 to IIc cutaneous melanoma. SMMS is a method of skin cancer removal involving repeated tissue removal and examination under a microscope to ensure the tumor is removed as much as possible while sparing healthy tissue. In SMMS, tissue sections are evaluated to determine whether additional tissue removal is needed. The standard method for evaluating the tissue is by using a specific stain called hematoxylin and eosin (H\&E) stains. PRAME is a cancer antigen that is being investigated as a diagnostic marker in certain types of cancer. Adding PRAME IHC analysis to standard SMMS staining methods may improve the accuracy for determining whether additional tissue removal is necessary for patients undergoing SMMS for stage 0 to IIc cutaneous melanoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07258446
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Immunohistochemistry Staining Method
Trials testing the same drug.
- NCT06311214 — Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastati · Phase 2 · recruiting
Other recruiting trials for Clinical Stage 0 Cutaneous Melanoma AJCC v8
Currently open trials in the same condition.
- NCT03819296 — Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer · Phase 1 · recruiting
- NCT03677739 — Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in · NA · active not recruiting
Other University of California, Davis trials
Trials by the same sponsor.
- NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
- NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
- NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
- NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
- NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07258446 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
- Last refreshed: 5 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07258446.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing